VBL Therapeutics to Report First Quarter 2018 Financial Results on May 17
May 02 2018 - 9:09AM
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Thursday, May
17 at 8:30am Eastern Time to report first quarter ended March 31,
2018 financial results.
Thursday, May 17th @ 8:30am Eastern TimeUS
Domestic:
877-222-6394International:
1-703-925-2702Conference
ID:
9993639Webcast:
https://edge.media-server.com/m6/p/zja7xger
Replays, Available through May 31, 2018US Domestic:
855-859-2056International:
1-404-537-3406Conference
ID:
9993639
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. The Company’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
positioned to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a Phase 3
trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024